UKUK

GSK shakes up its R&D

08.02.2012

London - GlaxoSmithKline re-adjusts its €3.7bn R&D budget. Following a review, three of 38 R&D units will be cut and four new ones installed, the UK drug company said in a statement on 7 Februray. Furthermore, six of the discovery units (DPUs) will get more money over the next years, while the budget of five will be cut. The shakeup is the outcome of a review started in November 2011. A panel of GSK executives and external experts heard presentations from the majority of its 38 DPUs. Scientists from each unit told the panel what they want to do over the next three years. In 2008 GSK broke up its R&D operations in tightly knit research groups of five to 70 scientists, who have to win their three-year based on performance. GSK is not the only one to look for a new R&D approach. British-Swedish rival Astra Zeneca hopes on outside innovation. Recently it announced that it will shift the search for external pre-Phase III assets into R&D, in a move to make the more and more important business development more science driven. GSK relies more on in house R&D and thinks it is on the right way. "I am very pleased with the energy, approach and productivity we are seeing from our scientists in these units", says Andrew Witty, CEO of GSK. Indeed, the return rate on the money spent on late stage pipeline projects was 11%. In 2011 it climbed o 12%, and Witty has declared he wants to push that rate to the 14% mark in the near future. Alas, even GSK is not immune against the odds of the pharmaceutical development business. On the same day of the announcement of the R&D successes GSK said that it had paused enrolment in its current Phase IIb clinical trials of GSK2251052 (GSK ‘052) for the treatment of complicated urinary tract infections due to a recently identified microbiological finding.

UKUK

02.04.2012

London - The not-for-profit UK Biobank, the most comprehensive health study in Britain, is now accessible to researchers from industry and academia. The resource, which contains some 1,000 pieces of health and lifestyle...

UKUK

21.03.2012

London – The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma,...

UKUK

07.03.2012

Nanopore sequencer Oxford Nanopore Technologies, a UK firm that promises its third-generation technology could theoretically sequence a human genome in 15 minutes, impressed scientists with the first public presentation of its...

UKUK

06.03.2012

GlaxoSmithKline (GSK) is further strengthening its activity in the area of rare diseases. The London-based pharma giant has signed an early-stage deal to develop and commercialise treatments for lysosomal storage disorders...

UKUK

27.02.2012

London/Montreal - Angiochem will collaborate with British pharma trust GlaxoSmithKline (GSK) plc on treatments for lysosomal storage diseases (LSD). London-based GSK will pay $300m, including up to $31.5m in upfront cash and...

UKUK

03.02.2012

London - AstraZeneca tries to shed some weight, anticipating a tough year ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company said in a statement. Research and development operations will be cancelled in...

UKUK

16.01.2012

Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture...

UKUK

22.12.2011

London - Nothing is well if the end is not well. For Astra Zeneca the end of 2011 isn't well at all. A new anti-ovarian cancer drug and a planned antidepressant have underperformed in tests. As a result, AstraZeneca will take a...

Displaying results 1 to 10 out of 396

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-uk/article/gsk-shakes-up-its-rd.html

Events

All Events

Partner-Events

Santiago de Compostela (ES)

BioSpain 2014

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • MERCK KGAA72.63 EUR4.35%
  • MAGFORCE7.30 EUR4.29%

FLOP

  • CYTOS0.21 CHF-8.70%
  • WILEX2.22 EUR-5.93%
  • CO.DON3.08 EUR-5.81%

TOP

  • PAION3.25 EUR31.0%
  • CO.DON3.08 EUR23.2%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • CYTOS0.21 CHF-19.2%
  • ADDEX3.25 CHF-18.8%
  • MEDIGENE3.86 EUR-17.0%

TOP

  • SANTHERA89.30 CHF2132.5%
  • PAION3.25 EUR245.7%
  • CO.DON3.08 EUR234.8%

FLOP

  • CYTOS0.21 CHF-94.7%
  • 4SC1.14 EUR-40.3%
  • BIOFRONTERA2.24 EUR-37.8%

No liability assumed, Date: 23.09.2014


Current issue

All issues

Product of the week

Products